SLC5A2 and diabetes mellitus: The aim of the current study was to reveal the prevalence of SGLT2 inhibitor use and its association with restenosis risk after femoropopliteal endovascular therapy for symptomatic peripheral artery disease in patients with diabetes mellitus.